Why Levetiracetam Should Be Administered Before Hemodialysis
Levetiracetam (Keppra) should NOT be administered before hemodialysis—it should be given AFTER hemodialysis to prevent premature drug removal and ensure adequate therapeutic levels.
The Pharmacokinetic Rationale
Levetiracetam is primarily renally eliminated and is significantly cleared by hemodialysis. Standard hemodialysis procedures remove approximately 50% of levetiracetam in 4 hours 1. When given before dialysis, the drug is substantially removed during the dialysis session, leading to:
- Subtherapeutic drug levels that can precipitate breakthrough seizures 2
- Wasted medication and ineffective dosing
- Increased risk of seizure activity during or immediately after dialysis
Evidence-Based Dosing Strategy
The FDA label explicitly states: "supplemental doses should be given to patients after dialysis" 1. This recommendation is echoed across multiple sources:
- Levetiracetam clearance during hemodialysis is substantial (approximately 50% removal in 4 hours) 1
- Post-dialysis administration prevents premature drug removal 3
- Patients have experienced generalized tonic-clonic seizures during hemodialysis when levels drop too low 2
Practical Dosing Recommendations
For patients with end-stage renal disease on hemodialysis:
- Administer the dose immediately AFTER each dialysis session
- This timing facilitates directly observed therapy (DOT) and ensures the drug remains in circulation 1
- Dosage adjustments are required: reduced frequency but maintaining adequate individual doses
- Consider therapeutic drug monitoring to ensure adequate levels without accumulation 1, 4
Clinical Consequences of Incorrect Timing
A case report documented a woman on levetiracetam who experienced generalized tonic-clonic seizures during hemodialysis due to subtherapeutic levels caused by dialytic removal 2. Hemodialysis significantly reduces serum levetiracetam concentration and can lead to subtherapeutic levels, necessitating close monitoring when dialysis is performed 2.
Research demonstrates that levetiracetam clearance during continuous renal replacement therapy (CRRT) is 31.2 ± 8.5 mL/min, and during sustained low-efficiency dialysis (SLED) is 74.0 ± 25.3 mL/min 3. There is substantial potential for subtherapeutic concentrations with current dosing strategies that don't account for these extracorporeal routes of elimination 3.
Dosing Comparison: Pre vs. Post-Dialysis
A study comparing dosing regimens found that post-hemodialysis dose levels recovered to 81.4% of pre-dialysis levels with twice-daily dosing versus only 65.7% with daily dosing 5. This underscores the importance of:
- Timing doses after dialysis
- Potentially using twice-daily regimens in dialysis patients
- Monitoring levels to ensure therapeutic range
Key Clinical Pitfall to Avoid
Never administer levetiracetam immediately before hemodialysis. Approximately 40% of the dose is removed when given just before dialysis, and far less is removed once the drug has distributed throughout the body 3. The post-dialysis timing ensures:
- Maximum drug retention
- Predictable pharmacokinetics
- Reduced seizure risk
- Facilitation of medication adherence monitoring
The evidence consistently supports post-dialysis administration as the standard of care for patients requiring both levetiracetam and hemodialysis 1, 3, 2, 5.